Roche joins the World Federation of Hemophilia Humanitarian Aid Program

Hemlibra donation will provide prophylactic treatment to as many as 1,000 people with haemophilia A over five years in countries where there is little or no access to haemophilia treatment Donation will substantially increase the number of people receiving prophylactic treatment for haemophilia A through the World Federation of Hemophilia Humanitarian Aid Program Roche today announced that it has joined the World Federation of Hemophilia (WFH) Humanitarian Aid Program, a landmark initiative leading the effort to change the lack of access to care and treatment for people with inherited bleeding disorders in developing countries. Together with Chugai and Genentech, members of the Roche Group, Roche's commitment to the WFH Program consists of a donation of Hemlibra (emicizumab), a prophylactic treatment for haemophilia A, and funding to deliver the WFH Program's integrated care development training to ensure that local infrastructure and medical expertise are available to optimise and appropriately use the donated Hemlibra. The donation will provide prophylactic treatment with Hemlibra to as many as 1,000 people with haemophilia A in developing countries, over the course of five years, with a focus on high-need patients, such as people of all ages with factor VIII inhibitors and children without factor VIII inhibitors.